Anita McElroy, MD, PhD
- Assistant Professor
- Department of Pediatrics
Education & Training
- MD, George Washington University
- PhD, University of California, San Diego
- McElroy AK, Akondy RS, Harmon JR, Ellebedy AH, Cannon D, Klena JD, Sidney J, Sette A, Metha AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Nichol ST and Spiropoulou. 2017. A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses. J Infect Dis. 215: 1862-1872.
- McElroy AK, Harmon JR, Flietstra TD, Campbell S, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Kratochvil CJ, Iwen PC, Smith PW, Ahmed R, Nichol ST and Spiropoulou CF. 2016. Kinetic Analysis of Biomarkers in a Cohort of US Patients with Ebola Virus Disease. Clin Infect Dis. 63: 460-467.
- McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, Lyon GM, Ribner BS, Varkey J, Sidney J, Sette A, Campbell S, Stroher U, Damon I, Nichol ST, Spiropoulou CF and Ahmed R. 2015. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA 112: 4719-4724.
- Dodd KA, McElroy AK, Jones ME, Nichol ST and Spiropoulou CF. 2013. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses. J Virol. 87: 6161-6171.
- Dodd KA, McElroy AK, Jones ME, Zaki SR, Nichol ST and Spiropoulou CF. 2014. Rift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model. PLoS Negl Trop Dis. 8: e2874.
We study the interactions that occur between the host immune system and emerging viral pathogens. To do this, animal model systems, clinical specimens from cases of human disease, and in vitro models are used. Previous work has focused on the Hantaviruses, Rift Valley fever virus (RVFV), Crimean-Congo hemorrhagic fever virus, Ebola virus and Lassa virus. Current studies are utilizing the mouse model to elucidate the role of T cells in immunity to RVFV.